David P. Southwell, Chief Executive Officer at TScan Therapeutics, Inc. (TCRX), bought 11,000 shares at $8.73 ($96K) on 2021-09-08, disclosed to the SEC on 2021-09-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| PTCT | SELL | 2023-04-19 | $1.2M | — | Filing → |
| PTCT | SELL | 2023-04-04 | $257K | — | Filing → |
| PTCT | SELL | 2023-03-29 | $897K | — | Filing → |